pages/clinical.md
... ...
@@ -10,8 +10,8 @@ link-citations: true
10 10
11 11
|Gene|Status|Entity|Therapy|Biomarkers|
12 12
|-|-|-|:---|:-----|
13
-|[BCL2](/BCL2)|not approved|DLBCL|venetoclax|Not applicable|
14
-|[BTK](/BTK#clinical-relevance)|not approved|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|
13
+|[BCL2](/BCL2)|ongoing|DLBCL|venetoclax|Not applicable|
14
+|[BTK](/BTK#clinical-relevance)|ongoing|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|
15 15
|[CD79B](/CD79B#clinical-relevance)|FDA approved|DLBCL|polatuzumab vedotin|ABC gene expression signature|
16 16
|[EZH2](/EZH2#clinical-relevance)|FDA approved|FL|tazemetostat|Mutation|
17 17
|[XPO1](/XPO1#clinical-relevance)|FDA approved|DLBCL|selinexor|Not applicable|